Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- SARS-CoV2
- Sponsor
- Heidelberg University
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- D5-20
- Last Updated
- 5 years ago
Overview
Brief Summary
Approximately 15% of patients with SARS-CoV-2 infection / COVID-19 develop a severe clinical course. This leads to hospitalization and potentially life threatening complications such as pneumonia and respiratory failure. Predictors for early detection and risk stratification are urgently needed. Moreover, only scarce information is available for long-term follow-up and late complications associated with infection. We therefore aimed to find predictors for severe courses of the novel disease as well as to establish strategies for therapeutic monitoring and follow-up.
Investigators
Dr. Frederik Trinkmann
Principal Investigator
Heidelberg University
Eligibility Criteria
Inclusion Criteria
- •SARS-CoV-2 infection / COVID 19
Exclusion Criteria
- •invasive ventilation
- •respiratory failure at admission
Outcomes
Primary Outcomes
D5-20
Time Frame: 1-6 months (outpatients, follow up)
frequency dependence of resistance as measured by oscillometry
FEV1/FVC
Time Frame: 1-6 months (outpatients, follow up)
forced expiratory volume in 1 s / forced vital capacity (as measured by spirometry)
TLCO
Time Frame: 1-6 months (outpatients, follow up)
Transfer factor for carbon monoxide
Secondary Outcomes
- comorbidities(at hospital admission and each follow (every 1-6 months))
- clinical symptoms(3-5 days intervals (inpatients), 1-6 months (outpatients, follow up))
- St. George's Respiratory Questionnaire total score(3-5 days intervals (inpatients), 1-6 months (outpatients, follow up))